^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Altera

    Company:
    Natera
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    8ms
    Longitudinal Analysis of Circulating Tumor DNA and Detection of Tumor Genomic Alterations Using Liquid Biopsy in Patients with Locally Advanced Esophagogastric Carcinoma (ASTRO 2023)
    Clearance of ctDNA may correlate to a favorable pCR and indicate a lower risk of relapse, guiding the strategy for adjuvant treatment. Personalized, tumor-informed sequence alterations of the 8 patients revealed a high frequency in TP53 alterations, which occurs early during development in esophagogastric cancer. This prospective study seeks to validate the application of ctDNA surveillance and tumor molecular alterations in a larger cohort after 5 years.
    Clinical • Tumor mutational burden • Liquid biopsy • Circulating tumor DNA • Metastases • Biopsy
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MAP2K1 (Mitogen-activated protein kinase kinase 1) • RB1 (RB Transcriptional Corepressor 1) • ARID1A (AT-rich interaction domain 1A) • CCNE1 (Cyclin E1) • PALB2 (Partner and localizer of BRCA2) • RNF43 (Ring Finger Protein 43) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • MSH3 (MutS Homolog 3) • MRE11A (MRE11 homolog, double strand break repair nuclease) • CCND3 (Cyclin D3) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1)
    |
    TP53 mutation
    |
    Signatera™ • Altera
    over1year
    Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease (clinicaltrials.gov)
    P=N/A; Not yet recruiting --> Recruiting | Initiation date: Jan 2022 --> Oct 2022 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial primary completion date • Enrollment open • Trial initiation date • Circulating tumor DNA
    |
    MLH1 (MutL homolog 1) • MSH2 (MutS Homolog 2) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    Signatera™ • Altera
    almost2years
    Real World Experience and Feasibility of Tissue Informed CGP and ctDNA Testing in a Cohort of NSCLC Patients (IASLC-WCLC 2022)
    Our study shows the feasibility of performing CGP and ctDNA testing using a single source of tissue in patients with NSCLC. CGP allowed for the identification of patients who may derive benefit from targeted therapies and ICIs, while also informing appropriate clinical trials. ctDNA analysis was congruent with clinical findings, and ctDNA dynamics were indicative of response to therapy.
    Real-world evidence • Clinical • Tumor mutational burden • Circulating tumor DNA
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    TMB-H
    |
    Signatera™ • Altera
    2years
    Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease (clinicaltrials.gov)
    P=N/A; N=45; Not yet recruiting; Sponsor:Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
    New trial • Circulating tumor DNA
    |
    MLH1 (MutL homolog 1) • MSH2 (MutS Homolog 2) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    Signatera™ • Altera